Other advancements include the development of: (i) a BIKE that additionally includes an anti-CD133 molecule to target cancer stem cells [152]; (ii) a TriKE that activates NK cells by binding NKp46 instead of presenting IL-15 [153]; and (iii) a nanoparticle-based TriKE that targets two NK cell activating receptors (CD16 and 4-1BB) and the tumor antigen EGFR, while simultaneously delivering the chemotherapeutic epirubicin [154]. The gene discussed is NCR1; the disease is cancer.